Cargando…

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development

Detalles Bibliográficos
Autores principales:	Faucette, Stephanie, Wagh, Santosh, Trivedi, Ashit, Venkatakrishnan, Karthik, Gupta, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867000/ https://www.ncbi.nlm.nih.gov/pubmed/29266809 http://dx.doi.org/10.1111/cts.12527

Ejemplares similares

Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
por: Ramamoorthy, Anuradha, et al.
Publicado: (2018)

Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development
por: Teng, Zhaoyang, et al.
Publicado: (2017)

Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned
por: Ro, Sunhee K., et al.
Publicado: (2023)

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
por: Ciani, Oriana, et al.
Publicado: (2023)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Trends and Characteristics of New Drug Approvals in China, 2011–2021
por: Su, Ling, et al.
Publicado: (2022)

Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval
por: Selwood, D
Publicado: (2004)

Anticancer drug development: preclinical screening, clinical trials and approval
por: Teicher, B A, et al.
Publicado: (2004)

Contemporary oncology trials, drug approvals and the physician-patient relationship
por: Schnog, John-John B., et al.
Publicado: (2022)

Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023)

Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
por: Demirci, Ebru, et al.
Publicado: (2023)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
por: Jiang, Di Maria, et al.
Publicado: (2019)

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology
por: Kurtin, Sandra E., et al.
Publicado: (2020)

Quantitative Translation in Immuno‐Oncology Research and Development
por: Bottino, Dean, et al.
Publicado: (2020)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial
por: Oda, Yoshihiro, et al.
Publicado: (2022)

Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
por: Albini, Adriana, et al.
Publicado: (2010)

Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities
por: Feng, Catherine, et al.
Publicado: (2021)

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
por: Chabner, Bruce A.
Publicado: (2017)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
por: Tateo, Valentina, et al.
Publicado: (2023)

US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera M., et al.
Publicado: (2023)

Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin
por: Okuyama, Ryo
Publicado: (2023)

GT198 Is a Target of Oncology Drugs and Anticancer Herbs
por: Pang, Junfeng, et al.
Publicado: (2021)

Screening of Natural Products and Approved Oncology Drug Libraries for Activity against Clostridioides difficile
por: Pal, Rusha, et al.
Publicado: (2020)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

An Assessment of the EMS Drug Overdose to Death Pathway from 2011 to 2017
por: Parmar, Samir T., et al.
Publicado: (2019)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
por: McPhail, Melanie, et al.
Publicado: (2022)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015
por: MacGregor, Andrea, et al.
Publicado: (2020)

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2022)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vjd1p7u5j2rsdsbgrb80as9voe